Nanopharmaceuticals as a solution to neglected diseases: Is it possible?

Acta Tropica

Volumn 170, Issue , 2017, Pages 16-42

  Islan, German A ^a   Durán, Marcela ^b   Cacicedo, Maximiliano L ^a   Nakazato, Gerson ^c   Kobayashi, Renata K T ^c   Martinez, Diego S T ^b,d   Castro, Guillermo R ^a   Durán, Nelson ^b,d  

^a Universidad Nacional de La Plata   (Argentina)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c STATE UNIVERSITY OF LONDRINA   (Brazil)

^d BRAZILIAN CENTER FOR RESEARCH IN ENERGY AND MATERIALS CNPEM   (Brazil)

Author keywords

Liposomes; Nanobiotechnology; Nanoemulsions; Nanoparticles; Neglected diseases; Solid lipid nanoparticles

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIMONY TARTRATE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; BENZNIDAZOLE; CHITOSAN NANOPARTICLE; CHLOROQUINE; CHLORPHENIRAMINE; CURCUMIN; DAPSONE; DIETHYLCARBAMAZINE; LIPOSOME; MEGLUMINE ANTIMONATE; METAL NANOPARTICLE; MILTEFOSINE; NANOCAPSULE; NANOCARRIER; NANOCRYSTAL; NIFURTIMOX; OXAMNIQUINE; PAROMOMYCIN; POLYMER; PRAZIQUANTEL; PRIMAQUINE; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; TRANSFORMING GROWTH FACTOR BETA1; TRICLOSAN; TUFTSIN; UNINDEXED DRUG; DRUG CARRIER; NANOPARTICLE;

BIOTECHNOLOGY; DISEASE TREATMENT; DRUG; EMULSION; LIPID; NANOPARTICLE;

ANTIMALARIAL DRUG RESISTANCE; BRUGIAN FILARIASIS; CHAGAS DISEASE; CONTROLLED DRUG RELEASE; DENGUE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; FILARIASIS; HUMAN; LEISHMANIASIS; LEPROSY; MALARIA; MALARIA FALCIPARUM; NANODEVICE; NANOEMULSION; NANOENCAPSULATION; NANOPHARMACEUTICS; NEGLECTED DISEASE; NONHUMAN; ONCHOCERCIASIS; PLASMODIUM BERGHEI INFECTION; REVIEW; RODENT MALARIA; SCHISTOSOMIASIS; SCHISTOSOMIASIS HAEMATOBIA; SCHISTOSOMIASIS JAPONICA; SCHISTOSOMIASIS MANSONI; SKIN LEISHMANIASIS; SUSPENSION; TOXOPLASMOSIS; TRYPANOSOMIASIS; TUBERCULOSIS; VISCERAL LEISHMANIASIS; NEGLECTED DISEASES; TROPICAL MEDICINE;

DENGUE VIRUS;

DRUG CARRIERS; HUMANS; LEISHMANIASIS; LEPROSY; LIPOSOMES; MALARIA; NANOPARTICLES; NEGLECTED DISEASES; ONCHOCERCIASIS; SCHISTOSOMIASIS; TROPICAL MEDICINE; TRYPANOSOMIASIS; TUBERCULOSIS;

EID: 85013627976     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2017.02.019     Document Type: Review

References (268)

1. Adesuji, E.T., Oluwaniyi, O.O., Adegoke, H.I., Moodley, R., Labulo, A.H., Bodede, O.S., Oseghale, C.O., Investigation of the larvicidal potential of silver nanoparticles against Culex quinquefasciatus: a case of a ubiquitous weed as a useful bioresource. J. Nanomat., 2016 (Article ID 4363751).
2. Adeyemi, O.S., Whiteley, C.G., Interaction of metal nanoparticles with recombinant arginine kinase from Trypanosoma brucei: thermodynamic and spectrofluorimetric evaluation. Biochim. Biophys. Acta 1840 (2014), 701–706.
3. Aditya, N.P., Vathsala, P.G., Vieira, V., Murthy, R.D.R., Souto, E.B., Advances in nanomedicines for malaria treatment. Adv. Colloid Interface Sci. 201–202 (2013), 1–17.
4. Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Woo Joo, S.W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., Nejati-Koshki, M., Liposome: classification, preparation, and applications. Nanoscale Res. Lett., 8, 2013, 102, 10.1186/1556-276X-8-102.
5. Alex, M.A., Chacko, A.J., Jose, S., Souto, E.B., Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur. J. Pharm. Sci. 42 (2012), 11–18.
6. Ali, M., Afzal, M., Misra, S., Bhattacharya, S.M., Amad, F.J., Dinda, A.K., Nanopharmaceuticals to target antifilarials: a comprehensive review. Expert Opin. Drug Del. 10 (2013), 665–675.
7. Ali, M., Afzal, M., Verma, M., Bhattacharya, S.M., Ahmad, F.J., Samim, M., Abidim, M.Z., Dinda, A.K., Therapeutic efficacy of poly (lactic-co-glycolic acid) nanoparticles encapsulated ivermectin (nano-ivermectin) against brugian filariasis in experimental rodent model. Parasitol. Res. 113 (2014), 681–691.
8. Amarji, B., Ajazuddin, B., Raghuwanshi, D., Vyas, S.P., Kanaujia, P., Lipid nano spheres (lnss) for enhanced oral bioavailability of amphotericin b: development and characterization. J. Biomed. Nanotechnol. 3 (2007), 264–269.
9. Araújo, S.C., Mattos, A.C.A., Teixeira, H.F., Coelho, P.M.Z., Nelson, D.L., Oliveira, M.C., Improvement of in vitro efficacy of a novel schistosomicidal drug by incorporation into nanoemulsions. Int. J. Pharm. 337 (2007), 307–315.
10. Arias, J.L., Unciti-Broceta, J.D., Maceira, J., Castillo, T., Hernández-Quero, J., Magez, S., Soriano, M., García-Salcedo, J.A., Nanobody conjugated PLGA nanoparticles for active targeting of African trypanosomiasis. J. Controlled Release 197 (2015), 190–198.
11. Baeumner, A.J., Schlesinger, N.A., Slutzki, N.S., et al. Biosensor for dengue virus detection: sensitive, rapid, and serotype-specific. Anal. Chem. 74 (2002), 1442–1448.
12. Bajpai, P., Vedi, S., Owais, M., Sharma, S.K., Saxena, P.N., Misra-Bhattacharva, S., Use of liposomized tetracycline in elimination of Wolbachia endobacterium of human lymphatic filariid Brugia malayi in a rodent model. J. Drug Target. 13 (2005), 375–381.
13. Balasegaram, M., Ritmeijer, K., Lima, M.A., Burza, S., Ortiz, G., Milani, B., Gaspani, S., Potet, J., Chappuis, F., Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin. Emerg. Drugs 17 (2012), 493–510.
14. Baldissera, M.D., Da Silva, A.S., Oliveira, C.B., Zimmermann, C.E.P., Vaucher, R.A., Santos, R.C.V., Rech, V.C., Tonin, A.A., Giongo, J.L., Mattos, C.B., Koester, L., Santurio, J.M., Monteiro, S.G., Trypanocidal activity of the essential oils in their conventional and nanoemulsion forms: in vitro tests. Exp. Parasitol. 134 (2013), 356–361.
15. Banyal, S., Malik, P., Tulia, H.S., Mukherjee, T.K., Advances in nanotechnology for diagnosis and treatment of tuberculosis. Curr. Opin. Pulm. Med. 19 (2013), 289–297.
16. Beatty, M.E., Stone, A., Fitzsimons, D.W., Hanna, J.N., Lam, S.K., Vong, S., et al. Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards. PLoS Negl. Trop. Dis., 4(11), 2010, e890.
17. Bender, A.R., von Briesen, H., Kreuter, J., Duncan, I.B., Rübsamen-Waigmann, H., Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob. Agents Chemother. 40 (1996), 1467–1471.
18. Benelli, G., Mehlhorn, H., Declining malaria, rising dengue and Zika virus: insights for mosquito vector control. Parasitol. Res., 115, 2016, 17471754, 10.1007/s004360164971z.
19. Benelli, G., Plant mediated biosynthesis of nanoparticles as an emerging tool against mosquitoes of medical and veterinary importance: a review. Parasitol. Res., 115, 2016, 2334, 10.1007/s0043601548009.
20. Bern, C., Maguire, J.H., Alvar, J., Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl. Trop. Dis., 2(10), 2008, e313, 10.1371/journal.pntd.0000313 (Epub 2008 Oct 29).
21. Bern, G., 2015. http://www.uptodate.com/contents/chagas-disease-antitrypanosomal-drug-therapy, accessesd on 12/07/2015.
22. Bhattacharya, R., Mukherjee, P., Biological properties of naked metal nanoparticles. Adv. Drug Deliv. Rev. 60 (2008), 1289–1306.
23. Bhuyan, B., Rajak, P., Nath, L.K., Nanocrystal technology and drug delivery. World J. Pharm. Res. 3 (2014), 2940–2971.
24. Binnebose, A.M., Haughney, S.L., Martin, R., Imerman, P.M., Narasimhan, B., Bellaire, B.H., Polyanhydride nanoparticle delivery platform dramatically enhances killing of filarial worms. PLoS Negl. Trop. Dis., 9, 2015, e0004173.
25. Bisht, V., Chattree, V., Khanna, N., Rao, D.N., Mycobacterial formulation in liposomes showed decreased expression of CD95/CD95L and caspase activity in T cells of leprosy patients. Curr. Appl. Phys. 5 (2005), 189–193.
26. Borges, V.R.A., Simon, A., Sena, A.R.C., Cabral, L.M., Sousa, V.P., Nanoemulsion containing dapsone for topical administration: a study of in vitro release and epidermal permeation. Int. J. Nanomed. 8 (2013), 535–544.
27. Bowman, M.C., Ballard, T.E., Ackerson, C.J., Feldheim, D.L., Margolis, D.M., Melander, C., Inhibition of HIV fusion with multivalent gold nanoparticles. J. Am. Chem. Soc. 130 (2008), 6896–6897.
28. Carneiro, Z.A., Maia, P.I.S., Sesti-Costa, R., Lopes, C.D., Pereira, T.A., Milanezi, C.M., Silva, M.A.P., Lopez, R.F.V., Silva, J.S., Deflon, V.M., In vitro and in vivo trypanocidal activity of H2bdtc-loaded solid lipid nanoparticles. PLoS Negl. Trop. Dis., 8(5), 2014, e2847, 10.1371/journal.pntd.0002847.
29. Castro, S.L., Soeiro, M.N., Higashi, K.O., Meirelles, M.N., Differential effect of amphotericin B on the three evolutive stages of Trypanosoma cruzi and on the host cell-parasite interaction. Braz. J. Med. Biol. Res. 26 (1993), 1219–1229.
30. Castro, L., Blázquez, M.L., Muñoz, J.A., González, F.G., Ballester, A., Mechanism and applications of metal nanoparticles prepared by bio-mediated process. Rev. Adv. Sci. Eng. 3 (2014), 1–18.
31. Cauerhff, A., Castro, G.R., Bionanoparticles, a green nanochemistry approach. Electron. J. Biotechnol., 16(3), 2013 (vol16-issuex-fulltext-x).
32. Cencig, S., Coltel, N., Truyens, C., Carlier, Y., Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome. PLoS Negl. Trop. Dis., 5(6), 2011, e1216, 10.1371/journal.pntd.0001216.
33. Chandy, A., Thakur, A.S., Singh, M.P., Mnigauha, A., A review of neglected tropical diseases: filariasis. Asian Pac. J. Trop. Med. 4 (2001), 581–586.
34. Chattree, V., Khanna, N., Bisht, V., Rao, D.N., Liposomal delivery of Mycobacterium leprae antigen(s) with murabutide and Trat peptide inhibits Fas-mediated apoptosis of peripheral blood mononuclear cells derived from leprosy patients. Indian J. Biochem. Biophys. 44 (2007), 386–393.
35. Clayton, R., Ohagen, A., Nicol, F., Del Vecchio, A.M., Jonckers, T.H., Goethals, O., Hertogs, K., Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes. Antiviral Res. 84 (2009), 142–149.
36. Cruz-Ortiz, N., Gonzalez, R.J., Lindblade, K.A., Richards, F.O. Jr., Sauerbrey, M., Zea-Flores, G., Dominguez, A., Oliva, O., Catú, E., Rizzo, N., Elimination of Onchocerca volvulus transmission in the Huehuetenango focus of Guatemala. J. Parasitol. Res., 2012, 2012, 638429, 10.1155/2012/638429.
37. D'Ambrosio, L., Centis, R., Sotgiu, G., Pontali, E., Spanevello, A., Migliori, G.B., New anti-tuberculosis drugs and regimens: 2015 update. Eur. Resp. Soc. (ERJ) Open Res., 1, 2015, 10.1183/23120541.00010-2015 (00010-2015).
38. Dangi, A., Dwivedi, V., Vedi, S., Owais, M., Misra-Bhattacharya, S., Improvement in the antifilarial efficacy of doxycycline and rifampicin by combination therapy and drug delivery approach. J. Drug Target. 18 (2010), 343–350.
39. Das, S., Roy, P., Mondal, S., Bera, T., Mukherjee, A., One pot synthesis of gold nanoparticles and application in chemotherapy of wild and resistant type visceral leishmaniasis. Colloids Surf. B Biointerfaces 107 (2013), 27–34.
40. Date, A.A., Joshi, M.D., Patravale, V.B., Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv. Drug Deliv. Rev. 59 (2007), 505–521.
41. De Jaeghere, F., Allémann, E., Kubel, F., Galli, B., Cozens, R., Doelker, E., Gurny, R., Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state. J. Controlled Release 68 (2000), 291–298.
42. De Mareuil, J., Mabrouk, K., Doria, E., Moulard, M., De Chasteigner, S., Oughideni, R., van Rietschoten, J., Rochat, H., De Waard, M., Sabatier, J.-M., Liposomal encapsulation enhances antiviral efficacy of SPC3 against human immunodeficiency virus type-1 infection in human lymphocytes. Antiviral Res. 54 (2002), 175–188.
43. Dembri, A., Montisci, M.J., Gantier, J.C., Chacun, H., Ponchel, G., Targeting of 3’-azido 3’-deoxythymidine (AZT)-loaded poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissues. Pharm. Res. 18 (2001), 467–473.
44. Demento, S.L., Bonafé, N., Cui, W., Kaech, S.M., Caplan, M.J., Fikrig, E., Ledizet, M., Fahmy, T.M., TLR9-targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J. Immunol. 185 (2010), 2989–2997.
45. Desjeux, P., Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27 (2004), 305–318.
46. Dhanasekaran, D., Thangaraj, R., Evaluation of larvicidal activity of biogenic nanoparticles against filariasis causing culex mosquito vector. Asian Pac. J. Trop. Dis. 3 (2013), 174–179.
47. Dhiman, R., Kathania, M., Raje, M., Majumdar, S., Inhibition of bfl-1/A1 by siRNA inhibits mycobacterial growth in THP-1 cells by enhancing phagosomal acidification. Biochim. Biophys. Acta 1780 (2008), 733–742.
48. Doktorovova, S., Souto, E.B., Silva, A.M., Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers – A systematic review of in vitro data. Eur. J. Pharm. Biopharm. 87 (2014), 1–18.
49. Dolatabadi, J.E.N., Valizadeh, H., Hamishehkar, H., Solid lipid nanoparticles as efficient drug and gene delivery systems: recent breakthroughs. Adv. Pharm. Bull. 5 (2015), 151–159.
50. Donnellan, S., Tran, L., Johnston, H., McLuckie, J., Stevenson, K., Stone, V., A rapid screening assay for identifying mycobacteria targeted nanoparticle antibiotics. Nanotoxicology 10 (2016), 761–769.
51. Doroud, D., Vatanara, A., Zahedifard, F., Gholami, E., Vahabpour, R., Najafabadi, A.R., Rafati, S., Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations. J. Pharm. Pharm. Sci. 13 (2010), 320–335.
52. Doroud, D., Zahedifard, F., Vatanara, A., Najafabadi, A.R., Rafati, S., Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice. Parasite Immunol. 33 (2011), 335–348.
53. Duarte, J.L., Amado, J.R., Oliveira, A.E., Cruz, R.A., Ferreira, A.M., Souto, R.N., Fernandes, C.P., Evaluation of larvicidal activity of a nanoemulsion of Rosmarinus officinalis essential oil. Rev. Brasil. Farmacogn. 25 (2015), 189–192.
54. Durán, N., Menck, C.F.M., Chromobacterium violaceum: a review on pharmacological and industrial perspectives. Crit. Rev. Microbiol. 27 (2001), 201–222.
55. Durán, N., Marcato, P.D., Teixeira, Z., Durán, M., Costa, F.T.M., Brocchi, M., State of the art of nanobiotechnology applications in neglected diseases. Curr. Nanosci. 5 (2009), 396–408.
56. Durán, N., Durán, M., Tasic, L., Marcato, P.D., Nanocrystal technologies in pharmaceuticals. Quim. Nova 33 (2010), 151–159.
57. Durán, N., Marcato, P.D., De Conti, R., Alves, O.L., Costa, F.T.M., Brocchi, M., Potential use of silver nanoparticles on pathogenic bacteria, their toxicity and possible mechanisms of action. J. Braz. Chem. Soc. 21 (2010), 949–959.
58. Durán, N., Marcato, P.D., Durán, M., Yadav, A., Gade, A., Rai, M., Mechanistic aspects in the biogenic synthesis of extracellular metal nanoparticles by peptides, bacteria, fungi and plants. Appl. Microbiol. Biotechnol. 90 (2011), 1609–1624.
59. Durán, M., Silveira, C.P., Durán, N., Catalytic role of traditional enzymes for biosynthesis of biogenic metallic nanoparticles: a mini-review. IET Nanobiotechnol. 9 (2015), 314–323.
60. Durán, N., Islan, G.A., Durán, M., Castrod, G.R., Nanobiotechnology solutions against aedes aegypti. J. Braz. Chem. Soc. 27 (2016), 1139–1149.
61. Durán, N., Durán, M., de Jesus, M.B., Fávaro, W.J., Nakazato, G., Seabra, A.B., Antimicrobial activity mechanisms of silver nanoparticles: an overview. Nanomed. NBM 12 (2016), 789–799.
62. Durán, N., Nakazato, G., Seabra, A.B., Antimicrobial activity of biogenic silver nanoparticles and silver chloride nanoparticles: an overview and comments. Appl. Microbiol. Biotechnol. 100 (2016), 6555–6570.
63. Dwivedi, P., Khatika, R., Chaturvedi, P., Khandelwal, K., Tanejac, I., Rajuc, K.S.R., Dwivedi, H., Singh, S.K., Gupta, P.K., Shukla, P., Tripathi, P., Singh, S., Tripathi, R., Wahajuddinc, R., Paliwal, S.K., Dwivedi, A.K., Mishra, R.R., Arteether nanoemulsion for enhanced efficacy against Plasmodium yoeliinigeriensis malaria: an approach by enhanced bioavailability. Colloids Surf. B Biointerfases 126 (2015), 467–475.
64. El-Nour, K.M.M.A., Eftaiha, A., Al-Warthan, A., Ammar, R.A.A., Synthesis and applications of silver nanoparticles. Arab. J. Chem. 3 (2010), 135–140.
65. El-Tonsy, M.M.S., Nanotechnology and nanomedicine applications in parasitic diseases. Parasitol. United J. 3 (2010), 19–26.
66. El-Zawawy, L.A., El-said, D., Mossallam, S.F., Ramadan, H.S., Younis, S.S., Triclosan and triclosan-loaded liposomal nanoparticles in the treatment of acute experimental toxoplasmosis. Exp. Parasitol. 149 (2015), 54–64.
67. Elechiguerra, J.L., Burt, J.L., Morones, J.R., Camacho-Bragado, A., Gao, X.-X., Lara, H.H., Yacaman, M.J., Interaction of silver nanoparticles with HIV-1. J. Nanobiotechnol., 3, 2005, 6, 10.1186/1477-3155-3-6.
68. Elsaid, M.M., Vitor, W.A., Frézard, F.J.G., Martins, M.S., Protection against toxoplasmosis in mice immunized with different antigens of Toxoplasma gondii incorporated into liposomes. Mem. Inst. Oswaldo Cruz (Rio de Janeiro) 94 (1999), 485–490.
69. Elsaid, M.M., Martins, M.S., Frézard, F.J.G., Braga, E.M., Vitor, R.W., Vertical toxoplasmosis in a murine model: protection after immunization with antigens of Toxoplasma gondii incorporated into liposomes. Mem. Inst. Oswaldo Cruz (Rio de Janeiro) 96 (2001), 99–104.
70. Fonseca, L.B., Viçosa, A.L., Mattos, A.C.A., Coelho, P.M.Z., Araújo, N., Zamith, H.P.S., Volpato, N.M., Nele, M., Pinto, J.C.C.S., Development of a brazilian nanoencapsulated drug for schistosomiasis treatment. Vigil Sanitária Debate 1 (2013), 82–88.
71. Fonseca, L.B., Nelem, M., Volpato, N.M., Seiceira, R.C., Pinto, J.C., Production of PMMA nanoparticles loaded with praziquantel through in situ miniemulsion polymerization. Macromol. React. Eng. 7 (2013), 54–63.
72. Frézard, F., Melo, A.L., Evaluation of the schistomicidal efficacy of lipossome-entrapped oxamniquine. J. Inst. Med. Trop. (São Paulo) 39 (1997), 91–100.
73. Frezza, T.F., Gremião, M.P.D., Zanotti-Magalhães, E.M., Magalhãe s, L.A., de Souza, A.L.R., Allegretti, S.M., Liposomal-praziquantel: efficacy against Schistosoma mansoni in a preclinical assay. Acta Trop. 128 (2013), 70–75.
74. Fuaad, A.A.H.A., Jia, Z., Zaman, M., Hartas, J., Ziora, Z.M., Lin, I.-C., Moyle, P.M., Batzloff, M.R., Good, M.F., Monteiro, M.J., Skwarczynski, M., Toth, I., Polymer–peptide hybrids as a highly immunogenic single-dose nanovaccine. Nanomedicine 9 (2013), 35–43.
75. Fuaad, A.A.H.A., Roubille, R., Pearson, M.S., Pickering, D.A., Loukas, A.C., Skwarczynski, M., Toth, I., The use of a conformational cathepsin D-derived epitope for vaccine development against Schistosoma mansoni. Bioorg. Med. Chem. 23 (2015), 1307–1312.
76. Gaafar, M.R., Mady, R.F., Diab, R.G., Shalaby, T.I., Chitosan and silver nanoparticles: promising anti-toxoplasma agents. Exp. Parasitol. 143 (2014), 30–38.
77. Gandhi, N.R., Shah, N.S., Andrews, J.R., Vella, V., Moll, A.P., Scott, M., Weissman, D., Marra, C., Lalloo, U.G., Friedland, G.H., HIV Coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Amer. J. Resp. Crit. Care Med. 181 (2010), 80–86.
78. Garg, T., Rath, G., Goyal, A.K., Inhalable chitosan nanoparticles as antitubercular drug carriers for an effective treatment of tuberculosis. Artif. Cells Nanomed. Biotechnol. 44 (2016), 997–1001.
79. Ghadiri, M., Vatanara, A., Doroud, D., Najafabadi, A.R., Paromomycin loaded solid lipid nanoparticles: characterization of production parameters. Biotechnol. Bioprocess Eng. 16 (2011), 617–623.
80. Ghosh, V., Mukherjee, A., Chandrasekaran, N., Formulation and characterization of plant essential oil based nanoemulsion: evaluation of its larvicidal activity against Aedes aegypti. Asian J. Chem. 25 (2013), S321–S323.
81. Glaziou, P., Sismanidis, C., Floyd, K., Raviglione, M., Global epidemiology of tuberculosis. Cold Spring Harb. Perspect. Med., 5, 2015, a017798, 10.1101/cshperspect.a017798.
82. Gong, T., Parniak, M., Gupta, P., Rohan, L., Nanodelivery of CSIC for enhanced solubility and rapid macrophage uptake. AIDS Res. Hum. Retr., 30, 2014, A143.
83. González-Martín, G., Figueroa, C., Merino, I., Osuna, A., Allopurinol encapsulated in polycyanoacrylate nanoparticles as potential lysosoma-tropic carrier: preparation and trypanocidal activity. Eur. J. Pharm. Biopharm. 49 (2000), 137–142.
84. Goulart, I.M.B., Goulart, L.R., Leprosy: diagnostic and control challenges for a worldwide disease. Arch. Dermatol. Res. 300 (2008), 269–290.
85. Govindarajan, M., Kadaikunnan, S., Alharbi, N.S., Benelli, G., Single-step biological fabrication of colloidal silver nanoparticles using Hugonia mystax: larvicidal potential against Zika virus, dengue, and malaria vector mosquitoes. Art. Cells, Nanomed. Biotechnol., 2016, 1–9.
86. Govindarajan, M., Vijayan, P., Kadaikunnan, S., Alharbi, N.S., Benelli, G., One-pot biogenic fabrication of silver nanocrystals using Quisqualis indica: effectiveness on malaria and Zika virus mosquito vectors, and impact on non-target aquatic organisms. J. Photochem. Photobiol. B: Biol. 162 (2016), 646–655.
87. Govindarajan, M., Hoti, S.L., Rajeswary, M., Benelli, G., One-step synthesis of polydispersed silver nanocrystals using Malva sylvestris: an eco-friendly mosquito larvicide with negligible impact on non-target aquatic organisms. Parasitology Res. 115 (2016), 2685–2695.
88. Guang, X.Y., Wang, J.J., He, Z.G., Chen, G.X., Din, G.L., Dai, J.J., Yang, X.H., Molluscicidal effects of nano-silver biological molluscicide and niclosamide. Chin. J. Schistosomiasis Control. 25 (2013), 503–505.
89. Gunaseelan, S., Gunaseelan, K., Deshmukh, M., Zhang, X., Sinko, P.J., Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs. Adv. Drug Deliv. Rev. 62 (2010), 518–531.
90. Haido, R.M., Barreto-Bergter, E., Amphotericin B-induced damage of Trypanosoma cruzi epimastigotes. Chem. Biol. Interact. 71 (1989), 91–103.
91. Ham, A., Cost, M., Sassi, A., Dezzutti, C., Rohan, L., Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm. Res. 26 (2009), 502–511.
92. Hawley, A.E., Illum, L., Davis, S.S., Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake. Pharm. Res. 14 (1997), 657–661.
93. Henriques, R.C.I., Ruiz, M.A., Arias, J.L., Nanotechnology and the diagnosis/treatment of leishmaniasis. Ars. Pharm. 55 (2014), 1–10.
94. Hirlekar, R., Garse, H., Kadam, V., Solid lipid nanoparticles and nanostructured lipid carriers: a review. Curr. Drug Ther. 6 (2011), 340–350.
95. Hleb, E.Y.L., Lapotko, D.O., Malaria theranostics using hemozoin-generated vapor nanobubbles. Theranostics 4 (2014), 761–769.
96. Hoerauf, A., Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr. Opin. Infec. Dis. 21 (2008), 673–681.
97. Hunsawong, T., Sunintaboon, P., Warit, S., Thaisomboonsuk, B., Jarmane, R.G., Yoon, I.-K., Ubol, S., Fernandez, S.A., Novel dengue virus serotype-2 nanovaccine induces robust humoral and cell-mediated immunity in mice. Vaccine 33 (2015), 1702–1710.
98. Hussain, A., Rehman, S.U., Aslam, S., Javed, N., Abbas, Z., Nano-gold particles mediated detection of ns1; an early diagnostic marker of dengue virus infection. J. Anim. Plant Sci. 24 (2014), 1110–1115.
99. Idrees, S., Ashfaq, U.A., RNAi: antiviral therapy against dengue vírus. Asian Pac. J. Trop. Biomed. 3 (2013), 232–236.
100. Isacchi, B., Arrigucci, S., La Marca, G., Bergonzi, M.C., Vannucchi, M.G., Novelli, A., Bilia, A.R., Conventional and long-circulating liposomes of artemisinin: preparation, characterization, and pharmacokinetic profile in mice. J. Liposome Res. 21 (2011), 237–244.
101. Isacchi, B., Bergonzi, M.C., Grazioso, M., Righeschi, C., Pietretti, A., Severini, C., Bilia, A.R., Artemisinin and artemisinin plus curcumin liposomal formulations: enhanced antimalarial efficacy against. Plasmodium berghei-infected mice. Eur. J. Pharm. Biopharm. 80 (2012), 528–534.
102. Islan, G.A., Mukherjee, A., Castro, G.R., Development of biopolymer nanocomposite for silver nanoparticles and ciprofloxacin controlled release. Int. J. Biol. Macromol. 72 (2015), 740–750.
103. Islan, G.A., Cortez Tornello, P., Abraham, G.A., Duran, N., Castro, G.R., Smart lipidic nanoparticles containing levofloxacin and DNase for lung delivery: design and characterization. Colloids Surf. B Biointerfaces 143 (2016), 168–176.
104. Jahanshahi, P., Zalnezhad, E., Sekaran, S.D., Adikan, F.R.M., Rapid immunoglobulin M-based dengue diagnostic test using surface plasmon resonance biosensor. Sci. Rep., 4, 2014, 3851.
105. Jaiswal, M., Dudhe, R., Sharma, P.K., Nanoemulsion: an advanced mode of drug delivery system. 3 Biotechnology 5 (2015), 123–127.
106. Jhaveri, A., Torchilin, V., Intracellular delivery of nanocarriers and targeting to subcellular organelles. Expert Opin. Drug Del. 13 (2016), 49–70.
107. Jung, S.H., Lim, D.H., Jung, S.H., Lee, J.E., Jeong, K.S., Seong, H., Shin, B.C., Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics. Eur. J. Pharm. Sci. 37 (2009), 313–320.
108. Junyaprasert, V.B., Morakul, B., Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian J. Pharm. Sci. 10 (2015), 13–23.
109. Karajgi, J.S., Vuas, S.P., A lymphotropic colloidal carrier system for diethylcarbamazine: preparation and performance evaluation. J. Microencapsul. 11 (1994), 539–545.
110. Karthik, S., Targeted delivery of diethylcarbamazine citrate to the lymphatics using solid lipid nanoparticles. J. Bioequiv. Availab., 6, 2014, 5, 10.4172/0975-0851.S1.019.
111. Kaur, I.P., Singh, H., Nanostructured drug delivery for better management of tuberculosis. J. Controlled Release 184 (2014), 36–50.
112. Kaur, M., Garg, T., Rath, G., Goyal, A.K., Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit. Rev. Ther. Drug Carrier Syst. 31 (2014), 49–88.
113. Kela, S.K., Kaur, C.D., Pharmaceutical nanoemulsions an ardent carrier for drug delivery. Indo Am. J. Pharm. Res. 3 (2013), 9202–9212.
114. Khalil, N.M., de Mattos, A.C., Carraro, T.C.M.M., Ludwig, D.B., Mainardes, R.M., Nanotechnological strategies for the treatment of neglected diseases. Curr. Pharm. Design 19 (2013), 7316–7329.
115. Khatik, R., Dwivedi, P., Khare, P., Kansal, S., Dube, A., Mishra, P.R., Dwivedi, A.K., Development of targeted 1, 2-diacyl-sn-glycero-3-phospho-l-serine-coated gelatin nanoparticles loaded with amphotericin B for improved in vitro and in vivo effect in leishmaniasis. Exp. Op. Drug Del. 11 (2014), 633–646.
116. Kroubi, M., Karembe, H., Betbeder, D., Drug delivery sytems in the treatment of african trypanomiasis infections. Exp. Opin. Drug Deliv. 6 (2015), 735–747.
117. Kuo, Y.-C., Chen, H.-H., Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate–sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood–brain barrier. Int. J. Pharm. 327 (2006), 160–169.
118. López-Gatell, H., Alpuche-Aranda, C.M., Santos-Preciadob, J.I., Hernández-Ávilaa, M., Dengue vaccine: local decisions, global consequences. Bull. WHO, 94(11), 2016, 850.
119. Löbenberg, R., Araujo, L., Kreuter, J., Body distribution of azidothymidine bound to nanoparticles after oral administration. Eur. J. Pharm. Biopharm. 44 (1997), 127–132.
120. Löbenberg, R., Araujo, L., von Briesen, H., Rodgers, E., Kreuter, J., Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J. Controlled Release 50 (1998), 21–30.
121. Lalloo, U.G., Ambaram, A., New antituberculous drugs in development. Curr. HIV/AIDS Rep. 7 (2010), 143–151.
122. Lam, J.K.-W., Liang, W., Chan, H.K., Pulmonary delivery of therapeutic siRNA. Adv. Drug Del. Rev. 64 (2012), 1–15.
123. Lamas, M.C., Villagi, L., Nocito, I., Bassani, G., Leonardi, D., Pascutti, F., Serra, E., Salomon, C.J., Development of parenteral formulations and evalutions of the biological activity of the trypanocide drug benznidazole. Int. J. Pharm. 307 (2006), 239–243.
124. Lembo, D., Cavalli, R., Nanoparticulate delivery systems for antiviral drugs. Antiviral Chem. Chemother. 21 (2010), 53–70.
125. Leroux, J.-C., Doelker, E., Gurny, R., Cozens, R., Roesel, J.L., Galli, B., Kubel, F., Doelker, E., Gurny, R., Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice. J. Pharm. Sci. 84 (1995), 1387–1391.
126. Leslie, T.A., Goldsmith, P.C., Dowd, P.M., Fungal and parasitic skin infestations – an update in treatment. Curr. Opin. Infect. Dis. 6 (1993), 658–667.
127. Leyke, S., Köhler-Sokolowska, W., Paulke, B.-R., Presber, W., Effects of nanoparticles in cells infected by Toxoplasma gondii. e-Polymers 12 (2013), 647–663.
128. Lima, M.L., de Albuquerque, C.N., Preparation and characterization of poli(ε-caprolactone) nanoparticles containing megazol: antichagasic agent. Braz. J. Pharm. Sci. 93 (2012), 493–498.
129. Lindoso, J.A.L., Costa, J.M.L., Queiroz, I.T., Goto, H., Review of the current treatments for leishmaniases. Res. Reports Trop. Med. 3 (2012), 69–77.
130. Liu, Y.-M., Zhu, K., Ma, H.-M., Determination of encapsulation efficiency and release of baicalein solid lipid nanoparticles in vitro. Pract. Pharm. Clin. Rem. 12 (2009), 104–105.
131. Lopes, R., Eleutério, C.V., Gonçalves, L.M.D., Cruz, M.E.M., Almeida, A.J., Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis. Eur. J. Pharm. Sci. 45 (2012), 442–450.
132. Lopes, R.M., Gaspar, M.M., Pereira, J., Eleutério, C.V., Carvalheiro, M., Almeida, A.J., Cruz, M.E.M., Liposomes versus lipid nanoparticles: comparative study of lipid-based systems as oryzalin carriers for the treatment of leishmaniasis. J. Biomed. Nanotechnol. 10 (2014), 1–11.
133. Lovelyn, C., Attama, A.A., Current state of nanoemulsions in drug delivery. J. Biomat. Nanobiotechnol. 2 (2011), 626–639.
134. Maia, P.I.S., Fernandes, A.G.A., Silva, J.J.N., Andricopulo, A.D., Lemos, S.S., Lang, E.S., Abram, U., Deflon, V.M., Dithiocarbazate complexes with the [M(PPh3)]2+ (M = Pd or Pt) moiety: synthesis, caracterization and anti-Tripanosoma cruzi activity. J. Inorg. Biochem. 104 (2010), 1276–1282.
135. Mainardes, R.M., Evangelista, R.C., Praziquantel-loaded PLGA nanoparticles: preparation and characterization. J. Microencapsul. 22 (2005), 13–24.
136. Mainardes, R.M., Chaud, M.V., Gremião, M.P.D., Evangelista, R.C., Development of praziquantel-loadd PLGA nanoparticles and evaluation of intestinal permeation by the everted gut Sac model. J. Nanosci. Nanotechnol. 6 (2006), 3057–3061.
137. Marinho, D.S., Casas, C.N.P.R., Pereira, C.C.A., Leite, I.C., Health economic evaluations of visceral leishmaniasis treatments: a systematic review. PLoS Negl. Trop. Dis., 9, 2015, e0003527.
138. Mehanna, M.M., Mohyeldin, S.M., Elgindy, N.A., Respirable nanocarriers as a promising strategy for antitubercular drug delivery. J. Controlled Release 187 (2014), 193–197.
139. Mehendale, R., Joshi, M., Patravale, V., Nanomedicines for treatment of viral diseases. Crit. Rev. Ther. Drug Carrier Syst. 30 (2013), 1–49.
140. Melo, A.L., Barcellos, N.M.S., Demicheli, C., Frézard, F., Enhanced schistosomicidal efficacy of tartar emetic encapsulated in pegylated liposomes. Int. J. Pharm. 255 (2003), 227–230.
141. Merkel, O.M., Rubinstein, I., Kissel, T., siRNA delivery to the lung: what's new?. Adv. Drug Del. Rev. 75 (2014), 112–128.
142. Meyerhoff, A., U.S. food and drug administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin. Infect. Dis. 28 (1999), 42–48.
143. Miller, J.L., Lachica, R., Sayce, A.C., Williams, J.P., Bapat, M., Dwek, R., Zitzmann, N., Liposome-mediated delivery of iminosugars enhances efficacy against dengue virus in vivo. Antimicrob. Agents Chemother. 56 (2012), 6379–6386.
144. Miranda, M.R., Canepa, G.E., Bouvier, L.A., Pereira, C.A., Trypanosoma cruzi: oxidative stress induces arginine kinase expression. Exp. Parasitol. 114 (2006), 341–344.
145. Mishra, A., Vuddanda, P.R., Singh, S., Intestinal lymphatic delivery of praziquantel by solid lipid nanoparticles: formulation design, in vitro and in vivo studies. J. Nanotechnol., 2014, 10.1155/2014/351693 (Article ID 351693).
146. Moghimi, S.M., Hawley, A.E., Christy, N.M., Gray, T., Illum, L., Davis, S.S., Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. FEBS Lett. 344 (1994), 25–30.
147. Molina, J., Urbina, J.A., Gref, R., Brener, Z., Rodriguez, J.M., Cure of experimental Chagas' disease by the bis-triazole D0870 incorporated into ‘stealth' polyethyleneglycol-polylactide nanospheres. J. Antimicrob. Chemoth. 47 (2001), 101–104.
148. Momeni, A., Rasoolian, M., Momeni, A., Navaei, A., Emami, S., Shaker, Z., Mohebali, M., Khoshdel, A., Development of liposomes loaded with anti-leishmanial drugs for the treatment of cutaneous leishmaniasis. J. Liposome Res. 23 (2013), 134–144.
149. Monteiro, L.M., Lione, V.F., Carmo, F.A., Amaral, L.H., Silva, J.H., Nasciutti, L.E., Rodrigues, C.R., Castro, H.C., Sousa, V.P., Cabral, L.M., Development and characterization of a new oral dapsone nanoemulsion system: permeability and in silico bioavailability studies. Int. J. Nanomed. 7 (2012), 5175–5182.
150. Moosavian Kalat, S.A., Khamesipour, A., Bavarsad, N., Fallah, M., Khashayarmanesh, Z., Feizi, E., Neghabi, K., Abbasi, A., Jaafari, M.R., Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice. Exp. Parasitol. 143 (2014), 5–10.
151. Moran, M., Guzman, J., Ropars, A.L., Illmer, A., The role of product development partnerships in research and development for neglected diseases. Intern. Health 2 (2010), 114–122.
152. Moreno, E., Schwartz, J., Larrea, E., Conde, I., Font, M., Sanmartín, C., Espuelas, S., Assessment of β-lapachone loaded in lecithin-chitosan nanoparticles for the topical treatment of cutaneous leishmaniasis in L. major infected BALB/c mice. Nanomed. NBM 11 (2015), 1993–2002.
153. Mourão, S.C., Costa, P.I., Salgado, H.R.N., Gremião, M.P.D., Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. Int. J. Pharm. 295 (2005), 157–162.
154. Mukherjee, S., Das, L., Kole, S., Karmakar, S., Datta, N., Das, P., Targeting of parasite specific immunoliposome-encapulated doxorubicin in the treatment of experimental visceral leishmaniasis. J. Infect. Dis. 189 (2004), 1024–1034.
155. Mungrue, K., The laboratory diagnosis of dengue virus infection, a review. Adv. Lab. Med. Int. 4 (2014), 1–8.
156. Murugan, K., Samidoss, C.M., Panneerselvam, C., Higuchi, A., Roni, M., Suresh, U., Chandramohan, B., Subramaniam, J., Madhiyazhagan, P., Dinesh, D., Rajaganesh, R., Alarfaj, A.A., Nicoletti, M., Kumar, S., Wei, H., Canale, A., Mehlhorn, H., Benelli, G., Seaweed synthesized silver nanoparticles: an ecofriendly tool in the fight against Plasmodium falciparum and its vector Anopheles stephensi?. Parasitol. Res. 114 (2015), 4087–4097.
157. Murugan, K., Dinesh, D., Paulpandi, M., Dakhellah Meqbel Althbyani, A., Subramaniam, J., Madhiyazhagan, P., Wang, L., Suresh, U., Mahesh Kumar, P., Mohan, J., Rajaganesh, R., Wei, H., Kalimuthu, K., Parajulee, M.N., Mehlhorn, H., Benelli, G., Nanoparticles in the fight against mosquitoborne diseases: bioactivity of Bruguiera cylindricasynthesized nanoparticles against dengue virus DEN2 (in vitro) and its mosquito vector Aedes aegypti (Diptera: culicidae). Parasitol. Res. 114 (2015), 4349–4361, 10.1007/s0043601546768.
158. Murugan, K., Aruna, P., Panneerselvam, C., Madhiyazhagan, P., Paulpandi, M., Subramaniam, J., Rajaganesh, R., Wei, H., Saleh Alsalhi, M., Devanesan, S., Nicoletti, M., Syuhei, B., Canale, A., Benelli, G., Fighting arboviral diseases: low toxicity on mammalian cells, dengue growth inhibition (in vitro) and mosquitocidal activity of Centroceras clavulatum synthesized silver nanoparticles. Parasitol. Res. 115 (2016), 651–662, 10.1007/s0043601547836.
159. Murugan, K., Panneerselvam, C., Samidoss, C.M., Madhiyazhagan, P., Suresh, U., Roni, M., Chandramohan, B., Subramaniam, J., Dinesh, D., Rajaganesh, R., Paulpandi, M., Wei, H., Aziz, A.T., Saleh Alsalhi, M., Devanesan, S., Nicoletti, M., Pavela, R., Canale, A., Benelli, G., In vivo and in vitro effectiveness of Azadirachta indica synthesized silver nanocrystals against Plasmodium berghei and Plasmodium falciparum, and their potential against malaria mosquitoes. Res. Vet. Sci. 106 (2016), 14–22.
160. Murugan, K., Panneerselvam, C., Aziz, A.T., Subramaniam, J., Madhiyazhagan, P., Hwang, J.S., Wang, L., Dinesh, D., Suresh, U., Roni, M., Higuchi, A., Nicoletti, M., Saleh Alsalhi, M., Benelli, G., Ecofriendly drugs from the marine environment: spongeweed synthesized silver nanoparticles are highly effective on Plasmodium falciparum and its vector Anopheles stephensi, with little non target effects on predatory copepods. Environ. Sci. Pollut. Res. 16 (2016), 16671–16685.
161. Nagle, A.S., Khare, S., Kumar, A.B., Supek, F., Buchynsky, A., Mathison, C.J.N., Chennamaneni, N.K., Pendem, N., Buckner, F.S., Gelb, M.H., Molten, V., Recent developments in drug discovery for Leishmaniasis and human African Trypanosomiasis. Chem. Rev. 114 (2014), 11305–11347.
162. Najer, A., Wu, D., Bieri, A., Brand, F., Palivan, C.G., Beck, H.P., Meier, W., Nanomimics of host cell membranes block invasion and expose invasive malaria parasites. ACS Nano 8 (2014), 12560–12571.
163. Neves, B.J., Andrade, C.H., Cravo, P.V.L., Natural products as leads in schistosome drug discovery. Molecules 20 (2015), 1872–1903.
164. Nzekwe, I.T., Azodo, V.I., Agubata, C.O., Naicker, B., Okore, V., Esimone, C.O., Preliminary formulation and characterization of solid lipid nanoparticles containing chloroquine and a P-glycoprotein inhibitor: influences of lipid-surfactant ratios. J. Chem. Pharm. Res. 7 (2015), 932–939.
165. Olbrich, C., Gessner, A., Kayser, O., Muller, R., Lipid-drug conjugate (LDC) nanoparticles as novel carrier system for the hydrophilic antitrypanosomal drug diminazenediaceturate. J. Drug Target. 10 (2012), 387–396.
166. Olliaro, P.L., Kuesel, A.C., Reeder, J.C., A changing model for developing health products for poverty-related infectious diseases. PLOS Neglect. Trop. Dis., 9, 2015, e3379, 10.1371/journal.pntd.0003379.
167. Omwoyo, W.N., Ogutu, B., Oloo, F., Swai, H., Kalombo, L., Melariri, P., Mahanga, G.M., Gathirwa, J.W., Preparation, characterization, and optimization of primaquine-loaded solid lipid nanoparticles. Int. J. Nanomed. 9 (2014), 3865–3874.
168. Owais, M., Varshney, G.C., Choudhury, A., Chandra, S., Gupta, C.M., Chloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistant Plasmodium Berghei infections in mice. Antimicrob. Agents Chemother. 39 (1995), 180–184.
169. Owais, M., Misra-Bhattacharya, S., Haq, W., Gupta, C.M., Immunomodulator tuftsin augments antifilarial activity of diethylcarbamazine against experimental brugian filariasis. J. Drug Target. 11 (2003), 247–251.
170. Ozeki, T., Tagami, T., Drug/polymer nanoparticles prepared using unique spray nozzles and recent progress of inhaled formulation. Asian J. Pharm. Sci. 9 (2014), 236–243.
171. Pandey, R., Khuller, G.K., Antitubercular inhaled therapy: opportunities, progress and challenges. J. Antimicrob. Chemother. 55 (2005), 430–435.
172. Papagiannaros, A., Bories, C., Demetzos, C., Loiseau, P.M., Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations. Biomed. Pharmacother. 59 (2005), 545–550.
173. Parashar, D., Aditya, N.P., Murthy, R.S.R., Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity. Drug Deliv. 44 (2014), 1–7.
174. Patel, V.B., Misra, A.N., Encapsulation and stability of clofazimine liposomes. J. Microencapsul. 16 (1999), 357–367.
175. Patel, V.B., Misra, A.N., Marfatia, Y.S., A topical dosage form of liposomal clofazimine: research and clinical implications. Pharmazie 54 (1999), 448–451.
176. Peh, A.E., Leo, Y.S., Toh, C.S., Current and nano-diagnostic tools for dengue infection. Front. Biosci. (Scholar Ed.) 3 (2013), 806–821.
177. Pereira, P.C.M., Navarro, E.C., Challenges and perspectives of Chagas disease: a review. J. Venom. Anim. Toxin. Incl. Trop. Dis., 19, 2013, 34, 10.1186/1678-9199-19-34.
178. Pieson, P., Steiger, R.F., Trouet, A., Liposomes in the chemotherapy of experimental murine malaria. T. Roy Soc. Trop. Med. Health, 73, 1979, 347.
179. Pieson, P., Steigert, R., Trouet, A., The disposition of free and liposomally encapsulated antimalarial primaquine in mice. Biochem. Pharmacol. 21 (1982), 3501–3507.
180. Pimentel, L.F., Jácome, A.T. Jr., Mosqueira, V.C.F., Santos-Magalhães, N.S., Application of pharmaceutical nanotechnology to the treatment of malaria. Braz. J. Pharm. Sci. 43 (2007), 504–514.
181. Pissinate, K., Santos, M.-D.É., Schaffazick, S.R., Oliveira, C.P., Vommaro, R.C., Guterres, S.S., Pohlmann, A.R., Souza, W., Pyrimethamine-loaded lipid-core nanocapsules to improve drug efficacy for the treatment of toxoplasmosis. Parasitol. Res. 113 (2014), 555–564.
182. Pollock, S., Nichita, N.B., Böhmer, A., Radulescu, C., Dwek, R.A., Zitzmann, N., Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 17176–17181.
183. Ponder, E., 2012. Global Health Primer 2012 Snapshot.
184. Prabhu, R.H., Patravale, V.B., Joshi, M.D., Polymeric nanoparticles for targeted treatment in oncology: current insights. Int. J. Nanomed. 10 (2015), 1001–1018.
185. Prasad, P.V.S., Kaviarasan, P.K., Leprosy therapy, past and present: can we hope to eliminate it?. Indian J. Dermatol. 55 (2010), 316–324.
186. Prasad, T.N.V.K.V., Kambala, V.S.R., Naidu, R., A critical review on biogenic silver nanoparticles and their antimicrobial activity. Curr. Nanosci. 4 (2001), 531–544.
187. Qureshi, S.R., Sahni, Y.P., Singh, S.K., Bhat, M.A., Dar, A.A., Quadri, S.A., Nanotechnology based drug delivery system. J. Pharm. Res. Opin. 1 (2011), 161–165.
188. Rai, M., Durán, N., (eds.) Metal Nanoparticles in Microbiology, 2011, Springer Verlag, Germany, 330.
189. Rai, M., Kon, K., Ingle, A., Durán, N., Galdiero, S., Galdiero, M., Broad-spectrum bioactivities of silver nanoparticles: the emerging trends and future prospects. Appl. Microbiol. Biotechnol. 98 (2014), 1951–1961.
190. Rai, M., Birla, S., Ingle, A., Gupta, I., Gade, A., Abd-Elsalam, K., Marcato, P.D., Durán, N., Nanosilver: an inorganic nanoparticle with myriad potential applications. Nanotechnol. Rev. 3 (2014), 281–309.
191. Rajakumar, G., Rahuman, A., Larvicidal activity of synthesized silver nanoparticles using Eclipta prostrata leaf extract against filariasis and malaria vectors. Acta Trop. 118 (2011), 196–203.
192. Ranjita, S., Loaye, A.S., Khalil, M., Present status of nanoparticle research for treatment of tuberculosis. J. Pharm. Pharm. Sci. 14 (2011), 100–116.
193. Rao, D.A., Forrest, M.L., Alani, A.W., Kwon, G.S., Robinson, J.R., Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. J. Pharm. Sci. 99 (2010), 2018–2031.
194. Ravichandran, R., In vivo pharmacokinetic stydies of albendazole nanoparticulate oral formulation for improve bioavailability. Int. J. Green Nanotechnol. Biomed. 2 (2010), B46–B52.
195. Ribeiro, R.R., Moura, E.P., Pimentel, V.M., Sampaio, W.M., Silva, S.M., Schettini, D.A., Alves, C.F., Melo, F.A., Tafuri, W.L., Demicheli, C., Melo, M.N., Frézard, F., Michalick, M.S.M., Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate. Antimicrob. Agents Chemother. 52 (2008), 2564–2572.
196. Ribeiro, T.G., Franca, J.R., Fuscaldi, L.L., Santos, M.L., Duarte, M.C., Lage, P.S., Castilho, R.O., An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis. Int. J. Nanomed., 9, 2014, 5341.
197. Robert-Gangneux, F., Dardé, M.-L., Epidemiology of and diagnostic strategies for toxoplasmosis. Clin. Microbiol. Rev. 25 (2012), 264–296.
198. Rodríguez-Morales, O., Monteón-Padilla, V., Carrillo-Sánchez, C.C., Rios-Castro, M., Martínez-Cruz, M., Carabarin-Lima, A., Arce-Fonseca, M., Experimental vaccines against Chagas disease: a journey through history. J. Immunol. Res., 2015 (Article ID 489758).
199. Rodrigues Caldeira, L., Ribeiro Fernandes, F., Ferreira Costa, D., Frézard, F., Crocco Afonso, L.C., Miranda Ferreira, L.A., Nanoemulsions loaded with amphotericin B: a new approach for the treatment of leishmaniasis. Eur. J. Pharm. Sci. 70 (2015), 125–131.
200. Rosas-Taraco, A.G., Higgins, D.M., Sánchez-Campillo, J., Lee, E.J., Orme, I.M., González-Juarrero, M., Local pulmonary immunotherapy with siRNA targeting TGFb1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice. Tuberculosis 91 (2011), 98–106.
201. Rossi-Bergmann, B., Pacienza-Lima, W., Marcato, P.D., De Conti, R., Durán, N., Therapeutic potential of biogenic silver nanoparticles in murine cutaneous leishmaniasis. J. Nano. Res. 20 (2012), 89–97.
202. Saha, S.K., Roy, P., Saini, P., Mondal, M.K., Chowdhury, P., Babu, S.P.S., Carbohydrate polymer inspired silver nanoparticles for filaricidal and mosquitocidal activities: a comprehensive view. Carbohyd. Polym. 137 (2016), 390–401.
203. Salazar, J., Ghanem, A., Müller, R.H., Möschwitzer, J.P., Nanocrystals: comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches. Eur. J. Pharm. Biopharm. 81 (2012), 82–90.
204. Salomon, C.J., First century of Chagas' disease: an overview on novel approaches to nifurtimox and benzonidazole delivery sytems. J. Pharma. Sci. 101 (2012), 888–894.
205. Salunkhe, R.B., Patil, S.V., Patil, C.D., Salunke, B.K., Larvicidal potential of silver nanoparticles synthesized using fungus Cochliobolus lunatus against Aedes aegypti (Linnaeus, 1762) and Anopheles stephensi Liston (Diptera; Culicidae). Parasitol. Res. 109 (2011), 823–831.
206. Santos, G.S., Pereira, G.G., Bender, E.A., Colomé, L.M., Guterres, S.S., De Carvalho, D.C.M., Weissmüller, G., Development and characterization of lipid nanoparticles for dapsone topical application. Quim. Nova 35 (2012), 1388–1394.
207. Santos-Magalhães, N.S., Mosqueira, V.C.F., Nanotechnology applied to the treatment of malaria. Adv. Drug Deliv. Rev. 62 (2010), 560–575.
208. Sayce, A.C., Miller, J.L., Zitzmann, N., Targeting a host process as na antiviral approach against dengue virus. Trends Microbiol. 18 (2010), 323–330.
209. Scholer, N., Krause, K., Kayser, O., Moller, R.H., Borner, K., Hahn, H., et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplamosis. Antimicrob. Agents Chemother. 45 (2001), 1771–1779.
210. Schwinte, P., Ramphul, N., Darcy, R., O'sullivan, J.F., Amphiphilic cyclodextrin complexation of Clofazimine. J. Inclus. Phenom. Macrocyclic. Chem. 47 (2013), 109–112.
211. Serizawa, T., Sawada, T., Okura, H., Wada, M., Hydrolytic activities of crystalline cellulose nanofibers. Biomacromolecules 14 (2013), 613–617.
212. Shah, L., Amiji, M., Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm. Res. 23 (2006), 2638–2645.
213. Shao, Z., Shao, J., Tan, B., Guan, S., Liu, Z., Zhao, Z., He, F., Zhao, J., Targeted lung cancer therapy: preparation and optimization of transferrin-decorated nanostructured lipid carriers as novel nanomedicine for co-delivery of anticancer drugs and DNA. Int. J. Nanomed. 10 (2015), 1223–1233.
214. Shegokar, R., Müller, R.H., Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int. J. Pharm. 399 (2010), 129–139.
215. Shubar, H.M., Lachanmaier, S., Haimesaat, M.M., Lohman, U., Mauludin, R., Mueller, R.H., Fitzner, R., Borner, K., Liesenfeld, O., SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood–brain barriers. J. Drug Target. 19 (2011), 114–124.
216. Silva, E.F., Orsi, M., Andrade, A.L., Domingues, R.Z., Silva, B.M., de Araújo, H.R., Pimenta, P.F.P., Diamond, M.S., Rocha, E.S.O., Kroon, E.G., Malaquias, L.C.C., Coelho, L.F., A tetravalent dengue nanoparticle stimulates antibody production in mice. J. Nanobiotechnol. 10 (2012), 1–5.
217. Singh, Y., Srinivas, A., Gangwar, M., Meher, J.G., Misra-Bhattacharya, S., Chourasia, M.K., Subcutaneously administered ultrafine PLGA nanoparticles containing doxycycline hydrochloride target lymphatic filarial parasites. Mol. Pharm. 13 (2016), 2084–2094.
218. Singh, K.K., Nanomedicine in malaria. Souza, E.B., (eds.) In Patenting Nanomedicines: Legal Aspects, Intellectual Properties and Grant Opportunities, 2012, Springer-Velag, Berlin, Germany, 401–434 (Chapter 14).
219. Siu, E., Ploss, A., Modeling malaria in humanized mice. Ann. N.Y. Acad. Sci. 1342 (2015), 29–36.
220. Smith, A.J., Kavuru, P., Wojtas, L., Zaworotko, M.J., Shytle, R.D., Cocrystals of quercetin with improved solubility and oral bioavailability. Mol. Pharm. 8 (2011), 1867–1876.
221. Soni, N., Prakash, S., Efficacy of fungus mediated silver and gold nanoparticles against Aedes aegypti larvae. Parasitol. Res. 110 (2012), 175–184.
222. Soni, N., Prakash, S., Synthesis of gold nanoparticles by the fungus Aspergillus niger and its efficacy against mosquito larvae. Rep. Parasitol. 2 (2012), 1–7.
223. Soni, N., Prakash, S., Fungal-mediated nano silver: an effective adulticide against mosquito. Parasitol. Res. 111 (2012), 2091–2098.
224. Soni, N., Prakash, S., Entomopathogenic fungus generated nanopart icles for enhancement of efficacy in Culex quinquefasciatus and Anopheles stephensi. Asian Pacif. J. Trop. Dis. 2 (2012), S356–S361.
225. Soni, N., Prakash, S., Possible mosquito control by silver nanoparticles synthesized by soil fungus (Aspergillus niger 2587). Adv. Nanopart. 2 (2013), 125–132.
226. Sosnik, A., Carcaboso, A.M., Glisoni, R.J., Moretton, M.A., Chiappetta, D.A., New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv. Drug Del. Rev. 62 (2010), 547–559.
227. Souza, A.L.R., Andreani, T., De Oliveira, R.N., Kiill, C.P., Dos Santos, F.K., Allegretti, S.M., Chaud, M.V., Souto, E.B., Silva, A.M., Gremião, M.P.D., In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment. Int. J. Pharm. 46 (2014), 31–37.
228. Souza, A.C.O., Nascimento, A.L., de Vasconcelos, N.M., Jeronimo, M.S., Siqueira, I.M., Santos, L.R., Cintra, D.O.S., Fuscaldi, L.L., Pires, O.R. Jr., Titze-de-Almeida, R., Borin, M.F., Bao, S.N., Martins, O.P., Cardoso, V.N., Fernandes, S.O., Mortari, M.R., Tedesco, A.C., Amaral, A.C., Felipe, M.S.S., Bocca, A.L., Activity and in vivo tracking of Amphotericin B loaded PLGA nanoparticles. Eur. J. Med. Chem. 95 (2015), 267–276.
229. Stecanella, L.A., Taveira, S.F., Marreto, R.N., Valadares, M.C., Vieira, M.S., Kato, M.J., Lima, E.M., Development and characterization of PLGA nanocapsules of grandisin isolated from Virola surinamensis: in vitro release and cytotoxicity studies. Braz. J. Pharmacog. 23 (2013), 153–159.
230. Stensrud, G., Sande, S.A., Kristensen, S., Smistad, G., Formulation and characterisation of primaquine loaded liposomes prepared by a pH gradient using experimental design. Int. J. Pharm. 198 (2000), 213–228.
231. Subramaniam, J., Murugan, K., Panneerselvam, C., Kovendan, K., Madhiyazhagan, P., Dinesh, D., Mahesh Kumar, P., Chandramohan, B., Suresh, U., Rajaganesh, R., Saleh Alsalhi, M., Devanesan, S., Nicoletti, M., Canale, A., Benelli, G., Multipurpose effectiveness of Couroupita guianensis synthesized gold nanoparticles: high antiplasmodial potential, field efficacy against malaria vectors and synergy with Aplocheilus lineatus predators. Environ. Sci. Pollut. Res. 23 (2016), 7543–7558.
232. Suganya, A., Murugan, K., Kovendan, K., Kumar, P.M., Hwang, J.S., Green synthesis of silver nanoparticles using Murraya koenigii leaf extract against Anopheles stephensi and Aedes aegypti. Parasitol. Res. 112 (2013), 1385–1397.
233. Sujitha, V., Murugan, K., Paulpandi, M., Panneerselvam, C., Suresh, U., Roni, M., Nicoletti, M., Higuchi, A., Madhiyazhagan, P., Subramaniam, J., Dinesh, D., Vadivalagan, C., Chandramohan, B., Alarfaj, A.A., Munusamy, M.A., Barnard, D.R., Benelli, G., Greensynthesized silver nanoparticles as a novel control tool against dengue virus (DEN2) and its primary vector Aedes aegypti. Parasitol. Res. 114 (2015), 3315–3325, 10.1007/s0043601545562.
234. Sutherland, C.S., Yukich, J., Goeree, R., Tediosi, F.A., A literature review of economic evaluations for a neglected tropical disease: human african Trypanosomiasis (“Sleeping Sickness”). PLoS Negl. Trop. Dis., 9, 2015, e0003397, 10.1371/journal.pntd.0003397.
235. Tachibana, H., Yoshihara, E., Kaneda, Y., Nakae, T., Protection of Toxoplasma gondii-infected mice by stearylamine-bearing liposomes. J. Parasitol. 76 (1990), 352–355.
236. Teles, F.R.R., Prazeres, D.M.F., Lima-Filho, J.L., Trends in dengue diagnosis. Rev. Med. Virol. 15 (2005), 287–302.
237. Tripathy, S., Roy, S., Review of age-old antimalarial drug to combat malaria: efficacy up- gradation by nanotechnology based drug delivery. Asian Pac. J. Trop. Med. 7 (2014), 673–679.
238. Tripathy, S., Das, S., Chakraborty, S.P., Sahu, S.K., Pramanik, P., Roy, S., Synthesis, characterization of chitosan-tripolyphosphate conjugated chloroquine nanoparticle and its in vivo anti-malarial efficacy against rodent parasite: a dose and duration dependent approach. Int. J. Pharm. 434 (2012), 292–305.
239. Tripathy, S., Mahapatra, S.K., Chahattopadhyyay, S., Das, S., Dash, S.K., Majumder, S., Pramanik, P., Roy, S., A novel chitosan based antimalarial drug delivery against Plasmodium berghei infection. Acta Trop. 128 (2013), 494–503.
240. Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R., Ford, N., Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 359 (2002), 2188–2194.
241. Tsai, M.J., Wu, P.C., Huang, Y.B., Chang, J.S., Lin, C.L., Tsai, Y.H., Fang, J.Y., Baicalein loaded in tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. Int. J. Pharm. 423 (2012), 461–470.
242. Turner, J.D., Tendongfor, N., Esum, M., Johnston, K.L., Langley, R.S., Ford, L., Faragher, B., Specht, S., Mand, S., Hoerauf, A., Enyong, P., Wanji, S., Taylor, M.J., Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulusin an area of Loa loacoendemicity: a randomized controlled trial. PLoS Negl. Trop. Dis., 4, 2010, e660, 10.1371/journal.pntd.0000660.
243. Turner, D., McGuinness, S.L., Leder, K., Leprosy: diagnosis and management in a developed setting. Internal Med. J. 45 (2015), 109–112.
244. Umeyor, C., Kenechukwu, F., Uronnachi, E., Chime, S., Opara, J.R., Attama, A., Recent advances in particulate anti-malarial drug delivery systems. A review. Int. J. Drug Deliv. 5 (2013), 1–14.
245. Unciti-Broceta, J.D., Arías, J.L., Maceira, J., Soriano, M., Ortiz-González, M., Hernández-Quero, J., Muñóz-Torres, M., Koning, H.P., Magez, S., Garcia-Salcedo, J., Specific cell targeting therapy bypasses drug resistance mechanisms in African Trypanosomiasis. PLoS Pathog. 11 (2015), 1–20.
246. Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H.M., Falzon, D., Floyd, K., Gargioni, G., Getahun, H., Gilpin, C., Glaziou, P., Grzemska, M., Mirzayev, F., Nakatani, H., Raviglione, M., WHO's new end TB strategy?. Lancet 385 (2015), 1799–1801.
247. Urbina, J.A., Specific treatment of Chagas’ disease: current status and new developments. Curr. Opin. Infect. Dis. 14 (2001), 733–741.
248. Van de Ven, H., Vermeersch, M., Matheeussen, A., Vandervoort, J., Weyenberg, W., Apers, S., Cos, P., Maes, L., Ludwig, L., PLGA nanoparticles loaded with the antileishmanial saponin β-aescin: factor influence study and in vitro efficacy evaluation. Int. J. Pharm. 420 (2011), 122–132.
249. Veerakumar, K., Govindarajan, M., Adulticidal properties of synthesized silver nanoparticles using leaf extracts of Feronia elephantum (Rutaceae) against filariasis, malaria, and dengue vector mosquitoes. Parasitol. Res. 113 (2014), 4085–4096.
250. World Health Organization, Preventive Chemotherapy in Human Helminthiasis: Coordinated Use of Anthelminthic Drugs in Control Interventions: a Manual for Health Professionals and Programme Managers. 2006, WHO, Geneva.
251. World Health Organization, TDR at a Glance, Geneva, Switzerland, 2010.
252. World Health Organization, Working to Overcome the Global Impact of Neglected Tropical Diseases: First WHO Report on Neglected Tropical Diseases, Geneva, Switzerland, 2010.
253. WHO, World Health Organization, Global tuberculosis report 2014, 2014.
254. WHO, Lepra. 2015 http://www.who.int/mediacentre/factsheets/fs101/en/.
255. WHO, Onchocerciasis. 2015 (Acessed October 2015) www.who.int/mediacentre/factsheets/fs374/en/.
256. WHO/HTM/TB, 2014.08. Geneva, World Health Organization, 2014.
257. Wang, W., Wang, L., Liang, Y.S., Susceptibility or resistance of praziquantel in human schistosomiasis. A review. Parasitol. Res. 111 (2012), 1871–1877.
258. Want, M.Y., Islamuddin, M., Chouhan, G., Ozbak, H.A., Hemeg, H.A., Dasgupta, A.K., Afrin, F., Therapeutic efficacy of artemisinin-loaded nanoparticles in experimental visceral leishmaniasis. Colloids Surf. B Biointerfaces 130 (2015), 215–221.
259. Woodson, T.S., Emerging technologies for the poor: how nanomedicine and public private partnerships are used to address diseases of poverty. Ph.D. Dissertation, 2014, Georgia Institute of Technology, August, USA.
260. Yadav, S.K., Srivastava, S., Lymphatic filariasis. an overview. Glob. J. Pharm. 8 (2014), 656–664.
261. Yang, L., Geng, Y., Li, H., Zhang, Y., You, J., Chang, Y., Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Pharmazie 64 (2009), 86–89.
262. Yang, X.H., Wang, J.J., Ge, J.Y., Wang, J.S., Dong, F.Q., Controlled synthesis of water soluble silver nanoparticles and the molluscicidal effect. Adv. Mat. Res. 399–401 (2011), 527–531.
263. Yuen, C.M., Jenkins, H.E., Rodriguez, C.A., Keshavjee, S., Becerra, M.C., Global and regional burden of isoniazid-resistant tuberculosis. Pediatrics 136 (2015), 1–10.
264. Zandi, K., Teoh, B.-T., Sam, S.-S., Wong, P.-F., Mustafa, M.R., AbuBakar, S., Novel antiviral activity of baicalein against dengue vírus. BMC Complem. Alternat. Med., 12, 2012, 214.
265. Zhang, G.J., Zhang, L., Huang, M.J., Luo, Z.H.H., Tay, G.K.I., Lim, E.J.A., Kang, T.G., Chen, Y., Silicon nanowire biosensor for highly sensitive and rapid detection of Dengue virus. Sens. Actuators B Chem. 146 (2010), 138–144.
266. Zhang, Y., Bai, J., Ying, J.Y., A stacking flow immunoassay for the detection of dengue-specific immunoglobulins in salivary fluid. Lab Chip 15 (2015), 1465–1471.
267. Zoppe, J.O., Ruottinen, V., Ruotsalainen, J., Rönkko, S., Leena-Sisko Johansson, L.-S., Hinkkanen, A., Jarvinen, K., Seppala, J., Synthesis of cellulose nanocrystals carrying tyrosine sulfate mimetic ligands and inhibition of alphavirus infection. Biomacromolecules 15 (2014), 1534–1542.
268. Zumla, A., George, A., Sharma, V., Herbert, N., Ilton, M., WHO's 2013 global report on tuberculosis: successes, threats, and opportunities. Lancet 382 (2013), 1765–1767.